3-methyl-4,5,6,7-tetrahydro-1,2-benzisoxazole | 24010-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-4,5,6,7-tetrahydro-1,2-benzisoxazole
• 英文别名: 3-methyl-4,5-tetramethyleneisoxazole；4,5,6,7-tetrahydro-3-methyl<1,2>benzoisoxazole；4,5,6,7-Tetrahydro-3-methylbenzisoxazol；3-methyl-4,5,6,7-tetrahydrobenzo[d]isoxazole；N-Methyl-4,5,6,7-tetrahydro-1,2-benzisoxazol；3-Methyl-4,5,6,7-tetrahydro-1,2-benzoxazole
• CAS: 24010-93-3
• 化学式: C₈H₁₁NO
• mdl: MFCD08063012
• 分子量: 137.181
• InChiKey: NPZFRRYICNZFBA-UHFFFAOYSA-N

物化性质

• 沸点：
  101-102 °C(Press: 11 Torr)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-4,5,6,7-tetrahydro-1,2-benzisoxazole 以 乙醇 为溶剂， 生成 4,5,6,7-四氢-2-甲基苯并恶唑
  参考文献：
  名称：

  Mechanistic studies on the photochemical reactions of isoxazoles

  摘要：

  DOI：

  10.1021/jo00863a003
• 作为产物：
  描述：

  (2-Methoxy-1-cyclohexen-1-yl)triphenylphosphonium-bromid 在 盐酸 、 sodium hydroxide 、 正丁基锂 、 盐酸羟胺 作用下， 以 水 为溶剂， 反应 18.5h， 生成 3-methyl-4,5,6,7-tetrahydro-1,2-benzisoxazole
  参考文献：
  名称：

  Oehler, Elisabeth; Zbiral, Erich, Chemische Berichte, 1980, vol. 113, # 9, p. 2852 - 2867

  摘要：

  DOI：

文献信息

• Rh(III)-Catalyzed Regioselective Synthesis of Pyridines from Alkenes and α,β-Unsaturated Oxime Esters
  作者：Jamie M. Neely、Tomislav Rovis

  DOI：10.1021/ja3104389

  日期：2013.1.9

  O-pivaloyl oximes are coupled to alkenes by Rh(III) catalysis to afford substituted pyridines. The reaction with activated alkenes is exceptionally regioselective and high-yielding. Mechanistic studies suggest that heterocycle formation proceeds via reversible C-H activation, alkene insertion, and a C-N bond formation/N-O bond cleavage process.

  α,β-不饱和的 O-新戊酰基肟通过 Rh(III) 催化与烯烃偶联，得到取代的吡啶。与活化烯烃的反应具有异常的区域选择性和高产率。机理研究表明，杂环的形成是通过可逆的 CH 活化、烯烃插入和 CN 键形成/NO 键裂解过程进行的。
• [EN] METHODS OF MODULATING CFTR ACTIVITY<br/>[FR] PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE CFTR
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2014210159A1

  公开（公告）日：2014-12-31

  The invention encompasses methods of modulating CFTR activity in a subject in need thereof comprising administering an effective amount of a compound of Formula (I). The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I).

  这项发明涵盖了在需要的受试者中调节CFTR活性的方法，包括向受试者施用化合物Formula (I)的有效量。该发明还涵盖了治疗与CFTR活性相关的疾病或与蛋白质稳态功能障碍相关的疾病的方法，包括向受试者施用化合物Formula (I)的有效量。
• [EN] PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVATIFS DE PYRIDINESULFONAMIDE POUVANT ÊTRE UTILISÉS COMME MODULATEURS TRAP1 ET LEURS UTILISATIONS
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188907A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了化合物的化学式（I）和药学上可接受的盐、溶剂化合物、水合物、多晶型、共晶体、互变异构体、立体异构体、同位素标记化合物以及其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能恢复PTEN诱导的激酶1（"PINK1"）功能丧失情况下的活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，和/或减少活性氧自由基的产生。所提供的化合物还可能对聚集或错误折叠的蛋白质（如α-突触核蛋白）进行重折叠或溶解。本公开还提供了包括所提供化合物的药物组合物；包括所提供化合物或药物组合物的试剂盒；以及使用所提供的化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE ET LEUR UTILISATION EN THÉRAPIE
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2016038045A1

  公开（公告）日：2016-03-17

  The present invention relates to pyrazolopyridine derivatives, which are useful as medicaments, pharmaceutical compositions comprising one or more of the pyrazolopyridine derivatives, and the use of one or more of the pyrazolopyridine derivatives in methods for treating and/or preventing a disease caused or mediated by a parasite of the family Trypanosomatidae.

  本发明涉及吡唑吡啶衍生物，其作为药物有用，包括一种或多种吡唑吡啶衍生物的制药组合物，以及使用一种或多种吡唑吡啶衍生物治疗和/或预防由Trypanosomatidae家族寄生虫引起或介导的疾病的方法。